Literature DB >> 25496195

Risk factors of Pneumocystis pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis.

X Iriart1, T Challan Belval, J Fillaux, L Esposito, R-A Lavergne, I Cardeau-Desangles, O Roques, A Del Bello, O Cointault, L Lavayssière, P Chauvin, S Menard, J-F Magnaval, S Cassaing, L Rostaing, N Kamar, A Berry.   

Abstract

Pneumocystis pneumonia (PCP) in solid organ transplant (SOT) recipients becomes rare in the immediate posttransplantation period thanks to generalized prophylaxis. We aimed to identify the predictive factors for PCP in the era of universal prophylaxis and to propose a strategy for preventing PCP beyond the first year after transplantation. In a retrospective case-control study, 33 SOT cases with PCP diagnosed between 2004 and 2010 were matched with two controls each to identify risk factors for PCP by uni- and multivariate analysis. All the patients benefited from 6 months of posttransplantation trimethoprim-sulfamethoxazole prophylaxis. Most PCP in SOT patients occurred during the second year posttransplantation (33%). By univariate analysis, age, nonuse of tacrolimus, total and CD4 lymphocyte counts, gamma-globulin concentration and cytomegalovirus (CMV) infection appeared to be PCP risk factors. In the final multivariate analysis, age (adjusted odds ratio [OR] 3.7, 95% confidence interval [CI]: 1.3-10.4), CMV infection (OR: 5.2, 95% CI: 1.8-14.7) and total lymphocyte count (OR: 3.9, 95% CI: 1.4-10.7) were found to be independently associated with PCP. The second year posttransplantation appeared to be the new period of highest risk of PCP. Age, CMV viremia and lymphocytes were the most pertinent predictive criteria to evaluate the risk of PCP in clinical practice. © Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  Clinical research; complication: infectious; disease: infectious; fungal; infection and infectious agents; infectious disease; lung; practice; risk assessment; risk stratification

Mesh:

Substances:

Year:  2014        PMID: 25496195     DOI: 10.1111/ajt.12947

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  23 in total

Review 1.  Infections after lung transplantation.

Authors:  Mario Nosotti; Paolo Tarsia; Letizia Corinna Morlacchi
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

2.  Pneumocystis pneumonia in liver transplant recipients.

Authors:  Xian-Liang Li; Zi-Xi Liu; Zhen-Jia Liu; Han Li; Benjamin Wilde; Oliver Witzke; Man Qi; Wen-Li Xu; Qiang He; Ji-Qiao Zhu
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

3.  Comparison of early and late Pneumocystis jirovecii Pneumonia in kidney transplant patients: the Korean Organ Transplantation Registry (KOTRY) Study.

Authors:  Gongmyung Lee; Tai Yeon Koo; Hyung Woo Kim; Dong Ryeol Lee; Dong Won Lee; Jieun Oh; Beom Seok Kim; Myoung Soo Kim; Jaeseok Yang
Journal:  Sci Rep       Date:  2022-06-23       Impact factor: 4.996

4.  m-TOR inhibitors and risk of Pneumocystis pneumonia after solid organ transplantation: a systematic review and meta-analysis.

Authors:  Maryam Ghadimi; Zinat Mohammadpour; Simin Dashti-Khavidaki; Alireza Milajerdi
Journal:  Eur J Clin Pharmacol       Date:  2019-08-03       Impact factor: 2.953

5.  Hypercalcaemia preceding diagnosis of Pneumocystis jirovecii pneumonia in renal transplant recipients.

Authors:  Jonathan Ling; Tara Anderson; Sanchia Warren; Geoffrey Kirkland; Matthew Jose; Richard Yu; Steven Yew; Samantha Mcfadyen; Alison Graver; William Johnson; Lisa Jeffs
Journal:  Clin Kidney J       Date:  2017-06-23

6.  Increased resistance of gram-negative urinary pathogens after kidney transplantation.

Authors:  Johannes Korth; Julia Kukalla; Peter-Michael Rath; Sebastian Dolff; Marco Krull; Hana Guberina; Anja Bienholz; Benjamin Wilde; Stefan Becker; Birgit Ross; Olympia Evdoxia Anastasiou; Andreas Kribben; Oliver Witzke
Journal:  BMC Nephrol       Date:  2017-05-19       Impact factor: 2.388

7.  Pneumocystis jiroveci pneumonia in kidney and simultaneous pancreas kidney transplant recipients in the present era of routine post-transplant prophylaxis: risk factors and outcomes.

Authors:  Neetika Garg; Margaret Jorgenson; Jillian Descourouez; Christopher M Saddler; Sandesh Parajuli; Brad C Astor; Arjang Djamali; Didier Mandelbrot
Journal:  BMC Nephrol       Date:  2018-11-21       Impact factor: 2.388

Review 8.  Pneumocystis Pneumonia in Solid-Organ Transplant Recipients.

Authors:  Xavier Iriart; Marine Le Bouar; Nassim Kamar; Antoine Berry
Journal:  J Fungi (Basel)       Date:  2015-09-28

9.  Severe infections in sarcoidosis: Incidence, predictors and long-term outcome in a cohort of 585 patients.

Authors:  Amélie Duréault; Catherine Chapelon; Lucie Biard; Fanny Domont; Léa Savey; Bahram Bodaghi; Valérie Pourcher; Matthieu Resche Rigon; Patrice Cacoub; David Saadoun
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

10.  Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years.

Authors:  Julius J Schmidt; Catherina Lueck; Stefan Ziesing; Matthias Stoll; Hermann Haller; Jens Gottlieb; Matthias Eder; Tobias Welte; Marius M Hoeper; André Scherag; Sascha David
Journal:  Crit Care       Date:  2018-11-19       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.